These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 7897118

  • 1. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents.
    Dehmer GJ, Gresalfi N, Daly D, Oberhardt B, Tate DA.
    J Am Coll Cardiol; 1995 Apr; 25(5):1069-75. PubMed ID: 7897118
    [Abstract] [Full Text] [Related]

  • 2. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH, Conard J, Szwarcer E, Verdy E, Vahanian A.
    Fundam Clin Pharmacol; 1988 Apr; 2(6):509-23. PubMed ID: 3149257
    [Abstract] [Full Text] [Related]

  • 3. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
    Farrehi PM, Zhu Y, Fay WP.
    J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
    [Abstract] [Full Text] [Related]

  • 4. Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase).
    Musselman DR, Tate DA, Oberhardt BJ, Abruzzini AF, Blauwet MB, Koch G, Dehmer GJ.
    Am J Cardiol; 1994 Mar 15; 73(8):544-9. PubMed ID: 8147298
    [Abstract] [Full Text] [Related]

  • 5. New developments in thrombolytic therapy.
    Collen D, Gold HK.
    Adv Exp Med Biol; 1990 Mar 15; 281():333-54. PubMed ID: 2129372
    [Abstract] [Full Text] [Related]

  • 6. The search for the ideal thrombolytic agent.
    Verstraete M.
    J Am Coll Cardiol; 1987 Nov 15; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [Abstract] [Full Text] [Related]

  • 7. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov 15; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

  • 8. In vivo effects of contrast media on coronary thrombolysis.
    Pislaru S, Pislaru C, Szilard M, Arnout J, Van de Werf F.
    J Am Coll Cardiol; 1998 Oct 15; 32(4):1102-8. PubMed ID: 9768739
    [Abstract] [Full Text] [Related]

  • 9. The effect of various contrast media on the activation of plasminogen by streptokinase or recombinant tissue plasminogen activator in vitro.
    Schilvold A, Bjørnsen S, Ing C, Brosstad F.
    Invest Radiol; 1994 Jul 15; 29(7):705-8. PubMed ID: 7960617
    [Abstract] [Full Text] [Related]

  • 10. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M, Zenker M, Klinge J, Keuper H, Harms D.
    J Pediatr Hematol Oncol; 1995 Aug 15; 17(3):260-4. PubMed ID: 7620925
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR, Miletich JP, Sobel BE, Jaffe AS.
    Thromb Res; 1988 Jun 01; 50(5):707-17. PubMed ID: 3137687
    [Abstract] [Full Text] [Related]

  • 12. Pharmacology of fibrinolysis.
    Haire WD.
    Chest; 1992 Apr 01; 101(4 Suppl):91S-97S. PubMed ID: 1555484
    [Abstract] [Full Text] [Related]

  • 13. Pharmacology of thrombolytic drugs.
    Verstraete M, Collen D.
    J Am Coll Cardiol; 1986 Dec 01; 8(6 Suppl B):33B-40B. PubMed ID: 3097100
    [Abstract] [Full Text] [Related]

  • 14. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A, Markart P, Kalinowski M, Ruppert C, Grimminger F, Seeger W.
    Am J Respir Cell Mol Biol; 1999 Dec 01; 21(6):738-45. PubMed ID: 10572071
    [Abstract] [Full Text] [Related]

  • 15. [New thrombolytic agents].
    Nguyen G, Samama M.
    Ann Biol Clin (Paris); 1987 Dec 01; 45(2):212-8. PubMed ID: 3113300
    [Abstract] [Full Text] [Related]

  • 16. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots.
    Carr ME, Carr SL, Merten SR.
    Haemostasis; 1995 Dec 01; 25(4):172-81. PubMed ID: 7557656
    [Abstract] [Full Text] [Related]

  • 17. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F.
    Arzneimittelforschung; 1988 Mar 01; 38(3A):474-8. PubMed ID: 3134901
    [Abstract] [Full Text] [Related]

  • 18. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V, Pannell R.
    Thromb Haemost; 1987 Jun 03; 57(3):372-3. PubMed ID: 3116707
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 20. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA, Huang TC, Keyt BA, Alevriadou BR.
    Ann Biomed Eng; 1998 Jun 30; 26(4):712-24. PubMed ID: 9662163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.